Curve Tirzepatide Review: Current Offer Unconfirmed

Curve’s current tirzepatide offer and purchase agreement remain unconfirmed. Our October 29, 2026 request to its official site failed during the TLS handshake, before a usable product page loaded. That access result is not evidence of closure or a judgment about existing care.³

Earlier prices need a current quote

Our July 20 listing recorded $225/month tirzepatide and a $135/month equivalent requiring 12-month prepayment. Those historical amounts are not verified current offers. We did not obtain an accepted quote, current inventory, annual charge, renewal schedule or refund contract on October 29.

Confirm the people behind the prescription

The earlier listing named Try Curve LLC, Beluga Health and VialsRx. We could not reconfirm their present roles or an assigned clinician or pharmacy. For context, our Coby Health review and Cora Health review discuss those brands' own care arrangements; shared names in older listings do not verify a current Curve prescription.

The brand-vs-compounded question

Our previous listing described Curve as offering compounded tirzepatide. That current preparation and availability were not re-established in the October 29 check. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

Clinical questions remain separate

For any proposed prescription, ask who provides follow-up and what happens if treatment is declined or changed; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

Compare actual offers

The old certification seal, all-state availability, same-day review and out-of-stock observations have not been refreshed. Do not treat an earlier seal as a current verification or a failed connection as a present stock report. Our Cora Health review is another provider to examine using its own accepted terms, and the provider comparison covers other options.